Join to View Full Profile
1515 Holcombe BlvdHouston, TX 77030
Phone+1 713-792-6161
Dr. Alhalabi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2017 - 2020
Corewell Health East Beaumont (Royal Oak)Residency, Internal Medicine, 2014 - 2017
Damascus University Faculty of MedicineClass of 2013, MD
Certifications & Licensure
FL State Medical License 2021 - Present
TN State Medical License 2023 - 2027
MI State Medical License 2016 - 2026
WA State Medical License 2023 - 2026
AL State Medical License 2023 - 2025
AZ State Medical License 2023 - 2025
GA State Medical License 2023 - 2025
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma Start of enrollment: 2023 Jun 13
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma Start of enrollment: 2019 Dec 18
Publications & Presentations
PubMed
- Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data.Tanya Jindal, Cindy Jiang, Omar Alhalabi, Amanda Nizam, Charles Nguyen
European Urology Oncology. 2025-04-01 - Neoadjuvant immune checkpoint therapy: Enabling insights into fundamental human immunology and clinical benefit.Kristen E Pauken, Omar Alhalabi, Sangeeta Goswami, Padmanee Sharma
Cancer Cell. 2025-03-19 - Efficacy and safety of nivolumab plus ipilimumab in patients with metastatic variant histology (non-clear cell) renal cell carcinoma.Mohammad Jad Moussa, Jaanki Khandelwal, Nathaniel R Wilson, Kiran L Malikayil, Devaki Shilpa Surasi
Journal for Immunotherapy of Cancer. 2025-02-12
Press Mentions
MD Anderson Research Highlights for February 26, 2025February 26th, 2025- MD Anderson Unveils Groundbreaking Research Breakthroughs – February 26, 2025February 26th, 2025
- Metastatic Prostate Cancer: Investigators Ponder New Path to Improve SurvivalSeptember 30th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
